Urol. praxi, 2015; 16(4): 152-153
Radionuclide therapy bone involvement in generalized prostate carcinoma
- Ústav nukleární medicíny VFN a 1. LF UK, Praha
Prostatic carcinoma is one of the most frequent malignant diseases in man. Majority of complications and near all mortality is associated
with metastatic and castration-resistant phase of prostate cancer (mCPRC). Except chemotherapy and targeted external radiotherapy
it is possible to administer bone seeking beta or alpha emitters. In this short review authors present the possibilities and advantages of
this therapy and its indications and contraindications.
Keywords: generalized carcinoma of the prostate, radionuclide therapy, alpha and beta emitters
Published: November 1, 2015 Show citation
References
- Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998; 17: 331-336.
Go to original source... 
Go to PubMed... - Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243-6249. Go to original source...
- Nieder C, Haukland E, Pawinski A, Dalhaug A. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer 2010; 10: 284. Go to original source... Go to PubMed...
- James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, RUK/06/019). Eur Urol. 2014; S0302-2838(14)00969-5. Go to original source...
- Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett 2012; 323: 135-146. Go to original source... Go to PubMed...
- Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63: 309-320. Go to original source... Go to PubMed...
- Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 940-945. Go to original source... Go to PubMed...
- Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88: 2934-2939. Go to original source...
- Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al.Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223. Go to original source...
- Oyen W, Sundram F, Haug AR, et al. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine centers. J Oncopathol. 2015; 3(1): 1-25. Go to original source...